Lazzati Andrea, Poghosyan Tigran, Goro Seydou, Gronnier Caroline
Department of Digestive and Endocrine Surgery, Avicenne University Hospital, AP-HP Sorbonne Paris Nord University, Bobigny, France; INSERM, UMR 1138, Centre de Recherche des Cordeliers, Centre Inria de Paris, Équipe HeKA, Paris, France.
Department of digestive, esogastric and bariatric surgery, Assistance Publique - Hôpitaux de Paris, Hôpital Bichat - Claude Bernard, Inserm UMRS 1149, Université Paris Cité, Paris, France.
Surg Obes Relat Dis. 2025 May;21(5):587-594. doi: 10.1016/j.soard.2024.12.002. Epub 2024 Dec 12.
The risk of esophageal cancer after bariatric surgery is a matter of debate.
This study aims to evaluate the risk of esophageal cancer following sleeve gastrectomy (SG) and gastric bypass (GB).
We extracted data from the national discharge database (Programme De Médicalisation des Systèmes d'Information) for patients who underwent bariatric surgery in France between 2007 and 2020. Adult patients undergoing SG or GB were included and followed until December 2022. The primary endpoints were the occurrence of esophageal and gastroesophageal junction (GEJ) cancers. The impact of bariatric procedures on cancer development was assessed using multivariate analysis, along with several sensitivity analyses to validate the findings.
Among the 370,271 patients included, 68.4% underwent SG and 31.6% underwent GB. The median follow-up duration was 7.4 years (interquartile range: 5.3-9.6 years), with approximately 81,000 patients followed for at least 10 years. A total of 96 cases of esophageal cancer were identified: 25 in the GB group and 71 in the SG group. The incidence rates were 2.6 per 100,000 person-years for GB and 3.9 for SG, resulting in an incidence rate ratio of .64 (95% confidence interval [CI]: .40-1.01, P = .055). In multivariate analysis, no significant difference in cancer incidence was found between SG and GB (hazard ratio [HR]: 1.60, 95% CI: .90-2.5, P = .06). Sensitivity analyses further confirmed these findings, showing similar nonsignificant differences across various models.
In this extensive national cohort of bariatric surgery patients, no significant differences were observed in the incidence of esophageal and GEJ cancer between SG and GB.
减肥手术后患食管癌的风险存在争议。
本研究旨在评估袖状胃切除术(SG)和胃旁路术(GB)后患食管癌的风险。
我们从法国国家医疗信息系统(Programme De Médicalisation des Systèmes d'Information)的全国出院数据库中提取了2007年至2020年间接受减肥手术患者的数据。纳入接受SG或GB的成年患者,并随访至2022年12月。主要终点是食管癌和胃食管交界(GEJ)癌的发生情况。使用多变量分析评估减肥手术对癌症发展的影响,并进行多项敏感性分析以验证研究结果。
在纳入的370271例患者中,68.4%接受了SG,31.6%接受了GB。中位随访时间为7.4年(四分位间距:5.3 - 9.6年),约81000例患者随访至少10年。共确诊96例食管癌:GB组25例,SG组71例。GB组的发病率为每10万人年2.6例,SG组为3.9例,发病率比为0.64(95%置信区间[CI]:0.40 - 1.01,P = 0.055)。在多变量分析中,SG和GB之间的癌症发病率无显著差异(风险比[HR]:1.60,95%CI:0.90 - 2.5,P = 0.06)。敏感性分析进一步证实了这些结果,在各种模型中均显示出类似的无显著差异。
在这个庞大的全国减肥手术患者队列中,SG和GB之间食管癌和GEJ癌的发病率没有显著差异。